Search Within

Timothy Chan

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (67)
  2. Meeting Abstract (16)
  3. Research Letter (2)
  4. Review (2)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (87)
  2. GSK Faculty (87)
  3. Human Oncology and Pathogenesis Program (87)
  4. Surgery (70)
  5. Department of Medicine (60)
  6. Sloan Kettering Institute Postdocs (53)

More Groups

People
  1. Abraham Hakimi (37)
  2. Fengshen Kuo (28)
  3. Luc Morris (27)
  4. Robert Motzer (24)
  5. Martin Voss (23)
  6. Vladimir Makarov (23)

More People

Years
  1. 2022 (10)
  2. 2021 (9)
  3. 2020 (13)
  4. 2019 (9)
  5. 2018 (6)
  6. 2017 (7)

More Years

Publications
  1. Journal of Clinical Oncology (16)
  2. Clinical Cancer Research (11)
  3. Nature (7)
  4. Nature Communications (5)
  5. Nature Genetics (5)
  6. Proceedings of the National Academy of Sciences of the United States of America (4)

More Publications

Publishers
  1. Nature Publishing Group (20)
  2. American Association for Cancer Research (17)
  3. American Society of Clinical Oncology (16)
  4. Oxford University Press (6)
  5. Biomed Central Ltd (4)
  6. Cell Press (4)

More Publishers

Results (87)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM)
    Meeting Abstract

    Omuro, A. M. P.; Beal, K.; Karimi, S.; Correa, D.; Chan, T. A.; DeAngelis, L. M.; Gavrilovic, I. T.; Nolan, C.; Hormigo, A.; Lassman, A. B.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma
    Meeting Abstract

    Omuro, A.; Beal, K.; Correa, D.; Chan, T.; DeAngelis, L.; Gavrilovic, I.; Nolan, C.; Hormigo, A.; Lassman, A. B.; Kaley, T.; more...
    Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers
    Journal Article

    Morris, L. G. T.; Taylor, B. S.; Bivona, T. G.; Gong, Y.; Eng, S.; Brennan, C. W.; Kaufman, A.; Kastenhuber, E. R.; Banuchi, V. E.; Singh, B.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2011)

    Fulltext@MSK | Save
  • The familial Parkinson disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin E
    Journal Article

    Veeriah, S.; Morris, L. G.; Solit, D.; Chan, T. A.
    Cell Cycle (2010)

    Fulltext@MSK | Save
  • Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies
    Journal Article

    Veeriah, S.; Taylor, B. S.; Meng, S.; Fang, F.; Yilmaz, E.; Vivanco, I.; Janakiraman, M.; Schultz, N.; Hanrahan, A. J.; Pao, W.; more...
    Nature Genetics (2010)

    Fulltext@MSK | Save
  • The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers
    Journal Article

    Veeriah, S.; Brennan, C.; Meng, S.; Singh, B.; Fagin, J. A.; Solit, D. B.; Paty, P. B.; Rohle, D.; Vivanco, I.; Chmielecki, J.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2009)

    Fulltext@MSK | Save
  • 14-3-3σ and p21 synergize to determine DNA damage response following Chk2 inhibition
    Journal Article

    Meng, S.; Arbit, T.; Veeriah, S.; Mellinghoff, I. K.; Fang, F.; Vivanco, I.; Rohle, D.; Chan, T. A.
    Cell Cycle (2009)

    Fulltext@MSK | Save